Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...

Acute Pyelonephritis II: Diagnostic Studies and Management

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Dosage Interval and Administration Route: Determination Methods

Dosage Interval and Administration Route: Determination Methods

A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with and without augmented renal clearance: A multicenter cohort.

Pharmacotherapy·2022

Same author

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates in a Hollow-Fibre Infection Model.

Antibiotics (Basel, Switzerland)·2022

Same author

Optimisation of treatments for oral <i>Neisseria gonorrhoeae</i> infection: Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial.

BMJ open·2022

Same author

Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches.

Transplant infectious disease : an official journal of the Transplantation Society·2022

Same author

Closed-loop control of continuous piperacillin delivery: An <i>in silico</i> study.

Frontiers in bioengineering and biotechnology·2022

Same author

Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation.

American journal of respiratory and critical care medicine·2022

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Antibiotic dosing for multidrug-resistant pathogen pneumonia.

Mohd H Abdul-Aziz¹, Jeffrey Lipman, Jason A Roberts

¹aBurns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia bSchool of Pharmacy, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia cDepartment of Intensive Care Medicine dPharmacy Department, Royal Brisbane and Women's Hospital eCentre for Translational Antiinfective Pharmacodynamics, The University of Queensland, Brisbane, Australia.

Current Opinion in Infectious Diseases

|December 29, 2016

Summary

Optimizing antibiotic dosing is crucial for treating multidrug-resistant nosocomial pneumonia in ICUs. Tailoring regimens based on pharmacokinetic/pharmacodynamic data improves outcomes for critically ill patients.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Related Experiment Videos

Last Updated: Mar 9, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Area of Science:

Critical Care Medicine
Infectious Diseases
Pharmacology

Background:

Nosocomial pneumonia caused by multidrug-resistant pathogens is a growing concern in intensive care units (ICUs).
These infections are linked to poorer patient outcomes.
Optimizing antibiotic dosing is a key strategy to improve treatment efficacy.

Purpose of the Study:

To review recent pharmacokinetic/pharmacodynamic (PK/PD) data relevant to antibiotic dosing for nosocomial pneumonia.
To highlight the challenges in treating infections caused by multidrug-resistant pathogens in critically ill patients.
To inform optimal antibiotic strategies for improved clinical outcomes.

Main Methods:

Review of current pharmacokinetic/pharmacodynamic data.
Analysis of challenges in antibiotic dosing for critically ill patients.
Evaluation of PK/PD principles for optimizing drug exposure.

Main Results:

Standard dosing guidelines often fail to account for altered physiology in critically ill patients.
Plasma drug concentrations may not correlate with concentrations at the infection site.
Aggressive dosing strategies, guided by PK/PD characteristics, are necessary for effective lung tissue drug exposure.

Conclusions:

Conventional antibiotic dosing strategies are associated with a higher risk of therapeutic failure in critically ill patients.
Alternative dosing strategies leveraging antibiotic PK/PD properties are essential.
Optimized antibiotic exposure through tailored dosing can lead to better therapeutic outcomes.